Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Bausch + LombEli Lilly
Last price
$20.01$1,368.34
Currency
USD
USD
$7.4B$1.2T
-44.29
-$0.31$30.81
0.560.39
0$6.69
00.51%
Sector
HealthHealth
Employees
13,00050,000
Ticker
$BLCO$LLY
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $BLCO or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.